Examination of the Effects of Liraglutide on the Mode of Action of Insulin Detemir

Novo Nordisk logo

Novo Nordisk

Status and phase

Completed
Phase 1

Conditions

Diabetes
Diabetes Mellitus, Type 2

Treatments

Drug: insulin detemir
Drug: liraglutide

Study type

Interventional

Funder types

Industry

Identifiers

NCT00873223
NN2211-3673

Details and patient eligibility

About

This trial is conducted in the United States. The aim of this clinical trial is to investigate whether chronic liraglutide administration affects the mode of action (pharmacokinetics) of insulin detemir

Enrollment

33 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Diagnosed with type 2 diabetes
  • BMI less than 45.0 kg/m2
  • Insulin naive
  • Currently treated with Oral Anti-Diabetic drugs (OADs) and metformin with a HbA1c between 7.0 and 9.5% or currently treated with metformin only with a HbA1c between 7.0 and 10.0%

Exclusion criteria

  • Any clinically significant disease other than type 2 diabetes
  • Currently using daily insulin
  • Thiazolidinione use or other injectable diabetes medications within the last 3 months

Trial design

Primary purpose

Treatment

Allocation

Non-Randomized

Interventional model

Crossover Assignment

Masking

None (Open label)

33 participants in 1 patient group

A
Experimental group
Treatment:
Drug: liraglutide
Drug: insulin detemir

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems